Enel SpA

Prysmian S.p.A.

Intesa Sanpaolo S.p.A.

DiaSorin S.p.A.

How the country is seeking a balance between debt and growth, and what new sectors will drive the economy in the coming years

"Made in Italy": not only food, fashion and cars - Freedom Finance interview in Italy

MoonLake Immunotherapeutics

Quotes of MoonLake Immunotherapeutics, a mid-cap biotech developing therapies for inflammatory skin and joint diseases, <a href="https://finance.yahoo.com/quote/MLTX/">plunged</a>&nbsp;90% yesterday, September 29, after the company <a href="https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-reports-week-16-results-vela-phase-3">reported</a>&nbsp;disappointing phase III trial results for its lead candidate sonelokimab. Investors staged a massive selloff, erasing most of the company’s market value.

MoonLake shares crash 90% after mixed phase III trial data of skin disease drug

aTyr Pharma, Inc.

Freedom Broker and other analysts have downgraded aTyr Pharma, a small-cap developer of therapies for pulmonary sarcoidosis, after its lead drug candidate failed to show meaningful results over placebo in final-phase trials. Freedom Broker analysts said the outcome reduces the likelihood of approval and undermines the company’s financial outlook.

Shares of aTyr plunge 80%, analysts downgrade ratings as lead drug fails trial

How to invest in pharmaceutical and biotech companies? Why, despite many scientific breakthroughs and sales hits such as Ozempic or Wegovy, does the pharmaceutical sector lag behind the technology sector in capitalization growth? What companies and products should an average investor follow and what mistakes should he avoid - these and other questions were answered by Ilya Yasny, co-founder of LanceBio Ventures, a fund specializing in biotechnology and investments in the pharmaceutical industry, in a video interview for the program "Oninvest: What's Next".

Ilya Yasny: "It is easy to lose a lot of money on investments in biotech companies"

Riot Platforms, Inc.

Illumina, Inc.

Teradyne, Inc.

Oklo Inc.

A recent Freedom Capital strategic outlook highlights small- and mid-cap opportunities across innovation economy sectors

Wellness, robots, biotech: Freedom names smid beneficiaries of innovation trends

MAIA Biotechnology, Inc.

Shares of micro cap MAIA Biotechnology <a href="https://finance.yahoo.com/quote/MAIA/">jumped</a>&nbsp;almost 9% yesterday, September 11, to end the day at $1.70 per share, an almost two-month high The gain followed the company's&nbsp;<a href="https://ir.maiabiotech.com/news-events/press-releases/detail/150/maia-biotechnology-highlights-positive-efficacy-data-from">announcement</a>&nbsp;that its experimental therapy for lung cancer, which is in the middle of phase II clinical trials, has demonstrated double the efficacy of standard treatment.

MAIA Biotechnology shares jump 9% on upbeat latest lung cancer therapy trial results

LB Pharmaceuticals

Preliminary trading in shares of LB Pharmaceuticals, a startup developing an oral therapy for acute schizophrenia, began Thursday on the Freedom Broker client trading system. The company’s stock, under the symbol&nbsp;<a href="https://tap.tradernet.global/to/quote/LBRX.US?utm_source=stocks&amp;utm_medium=LBRX.US&amp;utm_campaign=pfu9307038">LBRX</a>, will be listed later today, September 11, on the Nasdaq.

Shares of schizophrenia drugmaker LB Pharmaceuticals debut on Nasdaq

Ionis Pharmaceuticals, Inc.

Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatitis. Analysts were positive about the results. The company, which is known for its Spinraza drug for spinal muscular atrophy, could see its shares rise another 40%, according to some analysts' models.&nbsp;

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug

Voyager Technologies, Inc.

Redwire Corporation

MDA Space Ltd.

Intuitive Machines, Inc.

By 2035, the global space economy, from satellite communications to AI-driven analytics, will reach $1.8 trillion, according to <a href="https://www.mckinsey.com/featured-insights/themes/the-space-economy-is-projected-to-reach-1-8-trillion-by-2035">projections</a> by McKinsey and the World Economic Forum in Davos. Yet while most eyes are on Elon Musk’s SpaceX launches or visions of colonizing Mars, the real money is often being made in the less glamorous corners of the industry. One such player is the small-cap Redwire, the Motley Fool <a href="https://www.fool.com/investing/2025/06/25/7-space-stocks-id-buy-without-hesitation/">highlights</a>&nbsp;in a list of seven space stocks to buy "without hesitation." Wall Street <a href="https://www.marketwatch.com/investing/stock/rdw/analystestimates?mod=mw_quote_tab">expects </a>Redwire&nbsp;stock to double, even though the company remains unprofitable.

From space medicine to Mars colony: Redwire believed to offer triple-digit upside

Sarepta Therapeutics, Inc.

Shares of Sarepta Therapeutics, a small-cap developer of genetic medicines to treat rare neuromuscular and central nervous system diseases, soared 14% yesterday, July 29. The driver of the gains was the announcement that U.S. health regulators had authorized the biotech to resume shipments of its gene therapy that accounts for the majority of its revenue. Still, analysts&nbsp;caution that sales momentum will need to be maintained for the company to make a looming debt repayment.&nbsp;

Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume


Telomir Pharmaceuticals, Inc.

Zacks says take a look at the stock ahead of human trials of Telomir's primary drug early next year



Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Viking Therapeutics, a clinical-stage biotech developing, among other things, an oral weight-loss drug, has reported a net loss a third bigger than the market expected and is set to further increase R&amp;D spending. That said, the company is still considered a leading small-/mid-sized player in the weight-loss drug market and could pose a threat to Novo Nordisk and Eli Lilly with their injected therapies, Wall Street believes.&nbsp;